These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Assessing congenital malformation risk from medications used in pregnancy: The contribution of NBDPS in pregnancy labeling of prescription drug products. Tassinari MS, Sahin L, Yao LP. Birth Defects Res A Clin Mol Teratol; 2015 Aug; 103(8):718-20. PubMed ID: 26223007 [Abstract] [Full Text] [Related]
43. The Antiretroviral Pregnancy Registry Interim Report. Preboth M. Am Fam Physician; 2000 Apr 01; 61(7):2265. PubMed ID: 10779261 [No Abstract] [Full Text] [Related]
50. A strike against preemption. Nat Biotechnol; 2009 May 01; 27(5):397. PubMed ID: 19430422 [Abstract] [Full Text] [Related]
51. Labeling and manufacturing standards proposed for all dietary supplements. Horrigan B, Block B. Altern Ther Health Med; 2003 May 01; 9(3):22. PubMed ID: 12776471 [No Abstract] [Full Text] [Related]
52. Implications for the FDA/Center for Veterinary Medicine (CVM). Geyer RE. J Am Vet Med Assoc; 1993 May 15; 202(10):1718-23. PubMed ID: 8514592 [No Abstract] [Full Text] [Related]
53. Labeling regulations: 'prescribe as directed'. Regier H. J Leg Med (N Y); 1974 May 15; 2(5):48-51. PubMed ID: 4548706 [No Abstract] [Full Text] [Related]
54. Drugs in pregnancy and their effects on pre- and postnatal development. Kelsey FO. Res Publ Assoc Res Nerv Ment Dis; 1973 May 15; 51():233-43. PubMed ID: 4590403 [No Abstract] [Full Text] [Related]
55. Use of drugs for unapproved indications: your legal responsibility. Eye Ear Nose Throat Mon; 1972 Dec 15; 51(12):493-5. PubMed ID: 4637969 [No Abstract] [Full Text] [Related]